Two Sigma Investments, LP Leap Therapeutics, Inc. Transaction History

Two Sigma Investments, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.29 - $0.72 $16,900 - $41,960	-58,279 Reduced 59.43%	39,790 $13,000
Q4 2022 Feb 14, 2023	BUY	$0.42 - $0.78 $41,188 - $76,493	98,069 New	98,069 $44,000
Q2 2022 Aug 15, 2022	SELL	$0.96 - $1.91 $406,142 - $808,054	-423,065 Reduced 79.26%	110,683 $127,000
Q1 2022 May 16, 2022	SELL	$1.6 - $3.35 $1.57 Million - $3.29 Million	-983,297 Reduced 64.82%	533,748 $934,000
Q4 2021 Feb 14, 2022	BUY	$2.08 - $3.65 $2.53 Million - $4.44 Million	1,217,445 Added 406.36%	1,517,045 $4.92 Million

Q3 2021 Nov 15, 2021	BUY	$1.35 - $4.01 $404,460 - $1.2 Million	299,600 New	299,600 $1.2 Million
Q2 2021 Aug 16, 2021	SELL	$1.48 - $1.92 $363,710 - $471,840	-245,750 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$1.82 - $3.01 $242,707 - $401,401	-133,356 Reduced 35.18%	245,750 $467,000
Q4 2020 Feb 16, 2021	SELL	$1.49 - $2.37 $28,014 - $44,560	-18,802 Reduced 4.73%	379,106 $853,000
Q3 2020 Nov 16, 2020	BUY	$1.68 - $2.17 $521,149 - $673,151	310,208 Added 353.71%	397,908 $788,000
Q2 2020 Aug 14, 2020	BUY	$1.39 - $2.84 $121,902 - $249,068	87,700 New	87,700 $183,000

265K

Ticker LPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,021,400
Market Cap $198M
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate can...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.